Impact of extending device longevity on the long-term costs of implantable cardioverter-defibrillator therapy: A modelling study with a 15-year time horizon

Europace

Volumn 15, Issue 10, 2013, Pages 1453-1462

  Boriani, Giuseppe ^a   Braunschweig, Frieder ^b   Deharo, Jean Claude ^c   Leyva, Francisco ^d   Lubiński, Andrzej ^e   Lazzaro, Carlo ^f  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c TIMONE HOSPITAL   (France)

^d UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^e MEDICAL UNIVERSITY OF LODZ   (Poland)

^f Studio di Economia Sanitaria   (Italy)

Author keywords

Budget; Cardiac resynchronization therapy; Cost; Cost analysis; Device longevity; Economics; Implantable cardioverter defibrillator; Primary prevention; Sudden death

Indexed keywords

ARTICLE; CARDIAC PATIENT; CARDIAC RESYNCHRONIZATION THERAPY; CARDIAC RESYNCHRONIZATION THERAPY DEVICE; COST BENEFIT ANALYSIS; HEALTH CARE COST; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; LIFE EXPECTANCY; LONG TERM CARE; LONGEVITY; MEDICAL DEVICE COMPLICATION; NEW YORK HEART ASSOCIATION CLASS; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SUDDEN CARDIAC DEATH; SURVIVAL TIME; TREATMENT INDICATION;

BUDGET; CARDIAC RESYNCHRONIZATION THERAPY; COST; COST ANALYSIS; DEVICE LONGEVITY; ECONOMICS; IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR; PRIMARY PREVENTION; SUDDEN DEATH;

ARRHYTHMIAS, CARDIAC; BUDGETS; CARDIAC RESYNCHRONIZATION THERAPY; CARDIAC RESYNCHRONIZATION THERAPY DEVICES; COST SAVINGS; COST-BENEFIT ANALYSIS; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; ELECTRIC COUNTERSHOCK; EQUIPMENT DESIGN; EQUIPMENT FAILURE; HEALTH CARE COSTS; HEART FAILURE; HUMANS; MODELS, ECONOMIC; PRIMARY PREVENTION; PROSTHESIS DESIGN; PROSTHESIS FAILURE; TIME FACTORS; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT;

EID: 84885009154     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/eut133     Document Type: Article

References (39)

1. Zipes DP, Camm AJ, Borggrefe M, Buxton AE, Chaitman B, Fromer M et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the ACC/AHA Task Force and the ESC Committee for Practice Guidelines. Europace 2006;8:746-837.
2. Ezekowitz JA, Rowe BH, Dryden DM, Hooton N, Vandermeer B, Spooner C et al. Systematic review: implantable cardioverter defibrillators for adults with left ventricular systolic dysfunction. Ann Intern Med 2007;147:251-62.
3. Boriani G, Ricci R, Toselli T, Ferrari R, Branzi A, Santini M. Implantable cardioverter defibrillators: from evidence of trials to clinical practice. Eur Heart J Suppl 2007; 9(Suppl I):I66-73.
4. Leyva F, Fernandez Lozano I, Morgan J. Cardioverter-defibrillators: a cost or an investment? Europace 2011;13:ii25-31.
5. Wells G, Parkash R, Healey JS, Talajic M, Arnold JM, Sullivan S et al. Cardiac resynchronization therapy: a meta-analysis of randomized controlled trials. CMAJ 2011; 183:421-9.
6. Boriani G, Diemberger I, Biffi M, Martignani C. Cost-effectiveness of cardiac resynchronisation therapy. Heart 2012;98:1828-36.
7. BorianiG, Biffi M, Martignani C,Diemberger I, Valzania C, BertiniMet al. Expenditure and value for money: the challenge of implantable cardioverter defibrillators. QJM 2009;102:349-56.
8. Arribas F, Auricchio A,Wolpert C, Merkely B, Merino JL, Boriani G et al. The EHRA White Book. Europace 2012;14(Suppl 3):iii1-55.
9. Hauser RG. The growing mismatch between patient longevity and the service life of implantable cardioverter-defibrillators. J Am Coll Cardiol 2005;45:2022-5.
10. Gould PA, Krahn AD. Complications associated with implantable cardioverterdefibrillator replacement in response to device advisories. JAMA 2006;295: 1907-11.
11. Diemberger I, Biffi M, Martignani C, Boriani G. From lead management to implanted patient management: indications to lead extraction in pacemaker and cardioverterdefibrillator systems. Expert Rev Med Devices 2011;8:235e55.
12. Johansen JB, JørgensenOD, Møller M, Arnsbo P, Mortensen PT, Nielsen JC. Infection after pacemaker implantation: infection rates and risk factors associated with infection in a population-based cohort study of 46299 consecutive patients. Eur Heart J 2011;32:991-8.
13. DrummondMF, Schulper MJ, TorranceGW, O'Brien BJ, Stoddart GL. Methods for the Economic Evaluation of Health Care Programmes. 3rd ed. Oxford: Oxford University Press; 2005.
14. Maron BJ, Casey SA, Hauser RG, Aeppli DM. Clinical course of hypertrophic cardiomyopathy with survival to advanced age. J Am Coll Cardiol 2003;42:882-8.
15. Goldenberg I, Moss AJ, Maron BJ, Dick AW, Zareba W. Cost-effectiveness of implanted defibrillators in young people with inherited cardiac arrhythmias. Ann Noninvasive Electrocardiol 2005;10(4 Suppl):67-83.
16. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.NEngl J Med 2005; 352:225-37.
17. Yao G, Freemantle N, Calvert MJ, Bryan S, Daubert JC, Cleland JG. The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator. Eur Heart J 2007;28:42-51.
18. Moss AJ, Hall WJ, Cannom DS, Klein H, Brown MW, Daubert JP et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med 2009;361:1329-38.
19. Goldenberg I, Gillespie J, Moss AJ, Hall WJ, Klein H,McNitt S et al. Long-term benefit of primary prevention with an implantable cardioverter- defibrillator: an extended 8-year follow-up study of the Multicenter Automatic Defibrillator Implantation Trial II. Circulation 2010;122:1265-71.
20. Tang AS, Wells GA, Talajic M, Arnold MO, Sheldon R, Connolly S et al. Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med 2010;363:2385-95.
21. Briggs A, Schulper M, Claxton K. Decision Modelling for Health Economic Evaluation. Oxford: Oxford University Press; 2006.
22. Varani E, Balducelli M, Vecchi G, Aquilina M, Maresta A. Comparison of multiple drug-eluting stent percutaneous coronary intervention and surgical revascularization in patients with multivessel coronary artery disease: one-year clinical results and total treatment costs. J Invasive Cardiol 2007;19:469-75.
23. Cowie MR, Marshall D, Drummond M, FerkoN, MaschioM, EkmanMet al. Lifetime cost-effectiveness of prophylactic implantation of a cardioverter defibrillator in patients with reduced left ventricular systolic function: results of Markov modelling in a European population. Europace 2009;11:716-26.
24. Poole JE, Gleva MJ, Mela T, Chung MK, Uslan DZ, Borge R et al. Complication rates associated with pacemaker or implantable cardioverter- defibrillator generator replacements and upgrade procedures: results from the REPLACE registry. Circulation 2010;122:1553-61.
25. Landolina M, Gasparini M, Lunati M, Iacopino S, Boriani G, Bonanno C et al. Longterm complications related to biventricular defibrillator implantation: rate of surgical revisions and impact on survival: insights from the Italian Clinical Service Database. Circulation 2011;123:2526-35.
26. Gold MR, Siegel JE, Russel LB,Weinstein MC. (eds.) Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996.
27. Biffi M, Ziacchi M, Bertini M, Sangiorgi D, Corsini D, Martignani C et al. Longevity of implantable cardioverter-defibrillators: implications for clinical practice and health care systems. Europace 2008;10:1288-95.
28. Knops P, TheunsDA, Res JC, Jordaens L. Analysis of implantable defibrillator longevity under clinical circumstances: implications for device selection. Pacing Clin Electrophysiol 2009;32:1276-85.
29. Horlbeck FW, Mellert F, Kreuz J, Nickenig G, Schwab JO. Real-world data on the lifespan of implantable cardioverter-defibrillators depending on manufacturers and the amount of ventricular pacing. J Cardiovasc Electrophysiol 2012;23:1336-42.
30. Thijssen J, Borleffs CJ, van Rees JB, Man S, de Bie MK, Venlet J et al. Implantable cardioverter-defibrillator longevity under clinical circumstances: an analysis according to device type, generation, and manufacturer. Heart Rhythm 2012;9:513-9.
31. Richards EG. Calendars. In Urban SE, Seidelmann PK (eds) Explanatory Supplement to the Astronomical Almanac. 3rd ed. Mill Valley, CA: University Science Books; 2012, p. 598.
32. Briggs AH. Handling uncertainty in economic evaluation. In Drummond M, McGuire A (eds) Economic Evaluation in Health Care: Merging Theory with Practice. Oxford: Oxford University Press; 2001, p. 172-214.
33. Briggs AH, O'Brien BJ, Blackhouse G. Thinking outside the box: recent advances in the analysis and presentation of uncertainty in cost-effectiveness studies. Annu Rev Public Health 2002;23:377-401.
34. Biffi M, Ziacchi M, Bertini M, Gardini B, Mazzotti A, Massaro G et al. How to truly value implantable cardioverter-defibrillators technology: up-front cost or daily cost? Int J Technol Assess Health Care 2011;27:201-6.
35. Boriani G, Maniadakis N, Auricchio A, Müller-Riemenschneider F, Fattore G, Leyva F et al. Health technology assessment in interventional electrophysiology and device therapy: a position paper of the European Heart Rhythm Association. Eur Heart J 2013 February 7. [Epub ahead of print].
36. Camm J, Klein H, Nisam S. The cost of implantable defibrillators: perceptions and reality. Eur Heart J 2007;28:392-7.
37. Sorenson C, Tarricone R, Siebert M, Drummond M. Applying health economics for policy decision making: do devices differ from drugs? Europace 2011;13(Suppl 2): ii54-8.
38. Buxton MJ,DrummondMF, Van Hout BA, Prince RL, Sheldon TA, Szucs Tet al.Modelling in economic evaluation: an unavoidable fact of life. Health Econ 1997;6:217-27.
39. Weinstein MC, O'Brien B, Hornberger J, Jackson J, Johannesson M, McCabe C et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR task force on good research practices-modeling studies. Value Health 2003;6:9-17.